Neurocrine Biosciences (NBIX) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $166.05 +0.73%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
ARIS, COHR, ATS, More
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
ARIS, COHR, ATS, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of ($0.34), $0.02 worse than the analyst estimate of ($0.32).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- FatPipe, Inc. (FATN) Reports Q3 EPS of $0.09
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
